Anchorage Capital Group’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Anchorage Capital Group’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50,000	Closed	-$1.41K	–	8
2024 Q2	$1.41K	Hold	50,000	–	–	﹤0.01%	8
2024 Q1	$4.5K	Hold	50,000	–	–	﹤0.01%	9
2023 Q4	$5.26K	Hold	50,000	–	–	﹤0.01%	15
2023 Q3	$11.3K	Hold	50,000	–	–	﹤0.01%	17
2023 Q2	$13.1K	Hold	50,000	–	–	﹤0.01%	16
2023 Q1	$9K	Hold	50,000	–	–	﹤0.01%	17
2022 Q4	$10K	Hold	50,000	–	–	﹤0.01%	19
2022 Q3	$36K	Hold	50,000	–	–	﹤0.01%	23
2022 Q2	$27K	Hold	50,000	–	–	﹤0.01%	23
2022 Q1	$44K	Hold	50,000	–	–	﹤0.01%	22
2021 Q4	$112K	Hold	50,000	–	–	﹤0.01%	20
2021 Q3	$170K	Buy	+50,000	New	+$178K	﹤0.01%	23

Other funds holding DNA.WS

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $190M AUM 36.38% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Anchorage Capital Group's DNA.WS Position: Q3 2024 in Review

Anchorage Capital Group sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2024, closing a stake of 50,000 shares — an estimated $1.41K sold.

Anchorage Capital Group first reported a position in DNA.WS in Q3 2021 and held it in 12 quarters. The position peaked at $170K in Q3 2021. 5 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2024.

Anchorage Capital Group reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2024 after selling out during the quarter.
Anchorage Capital Group sold 50,000 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2024, an estimated $1.41K.
Anchorage Capital Group first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 12 quarters.
Anchorage Capital Group's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $170K in Q3 2021.
5 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2024.

Based on Anchorage Capital Group's 13F filing for Q3 2024, filed 14 Nov 2024.